On August 2022, FDA granted accelerated approval to T-DXd at the dose of 5.4 mg/kg q3w for HER2-mutant NSCLC,92 which showed less toxicity without jeopardizing efficacy when compared to the 6.4 mg/kg q3w dose in the DESTINY-Lung02.93 Here, ERBB2 is linked to non-small cell lung carcinoma.